Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Author Profile


Michael McGoon, MD

Mayo Clinic, Rochester

Professor of Medicine, Mayo Clinic
Rochester, Minn.

Board term ending: January 2015 (third term)

Dr. Mike McGoon is a consultant in the Division of Cardiovascular Diseases at the Mayo Clinic and Professor of Medicine at the Mayo Clinic College of Medicine. He attended college at Harvard and medical school at Johns Hopkins, where he also did his medical residency. He completed subspecialty cardiology training at Mayo and has been on staff there since 1983. Besides his involvement with pulmonary hypertension, Dr. McGoon specializes in cardiac pacemaker, defibrillator and cardiac re-synchronization device implantation and management. Dr. McGoon is also Chair of the REVEAL Registry Steering Committee.

Dr. McGoon has a long history with the Pulmonary Hypertension Association. He served as Chair of the Scientific Leadership Council from 2002-2004, the chair of the Board of Trustees from 2006-2008, and the Immediate Past-Chair from 2008-2010. Dr. McGoon has seats on both the Development and Strategic Planning Committees. He continues his membership in the Scientific Leadership Council and the PH Clinicians and Researchers.

He lives in Rochester, Minn. with his wife Bonnie and son Joe. His three grown daughters live in Phoenix, Minneapolis and Eugene. The McGoons are also PHA special event coordinators, hosting an annual event in the Rochester area to raise funds for PH research.

Learn more about Michael McGoon, MD...

 

Profile Photo

Journal Articles

  • Ambulatory Hemodynamic Monitoring in Pulmonary Arterial Hypertension Although an abnormality of pulmonary hemodynamics is the defining characteristic of pulmonary hypertension (PH), there is considerable debate about the optimal method of assessing pulmonary arterial pressure (PAP).
  • Award-Winning Abstracts Focus on Diagnostic Criteria, Impact of Calcium Channel Blockers The following abstracts were chosen at the 7th International Pulmonary Hypertension Conference & Scientific Sessions for their outstanding contribution to the advancement of knowledge in pulmonary hypertension.
  • Continuous Intravenous Epoprostenol for PAH: Highlighting Practical Issues, Special Considerations Continuous intravenous epoprostenol sodium (Flolan®) is a long-term, complex, and expensive therapy.
  • Diagnostic Dilemmas: Diastolic Heart Failure Causing Pulmonary Hypertension and Pulmonary Hypertension Causing Diastolic Dysfunction Left heart disease can cause pulmonary hypertension via multiple mechanisms. In the past, a normal ejection fraction and the absence of left-sided valve disease or congenital heart disease provided reassurance that pulmonary hypertension was not related to left-sided heart disease. However, it is now recognized that patients with clinical heart failure commonly have a normal ejection fraction, a syndrome referred to as diastolic heart failure or heart failure with normal ejection fraction.
  • Editor's Memo PHA Scientific Sessions Break New Ground, Providing Timely, Focused Venue for Current Research
  • PH Roundtable Bench to Bedside: Principles and Practice of Epoprostenol Therapy, from Maximizing Benefit to Minimizing Side Effects
  • Pulmonary Arterial Hypertension: Epidemiology and Registries Registries of pulmonary arterial hypertension (PAH) are important means by which to characterize the presentation and outcome of patients and to provide a basis for predicting the course of the disease. This article summarizes the published conclusions of the World Symposium of Pulmonary Hypertension task force that addressed registries and epidemiology of PAH.
  • Pulmonary Hypertension Care Centers Our understanding and management of pulmonary arterial hypertension (PAH) has advanced tremendously over the last 30 years. Numerous scientific discoveries have helped to elucidate underlying mechanisms. Registries dating from the National Institutes of Health (NIH)-sponsored Patient Registry for Primary Pulmonary Hypertension (PPH Registry) of the 1980s to the recent REVEAL and French National registries have provided valuable information on PAH's epidemiology, natural history, risk factors, and prognostic indicators. Clinical classifications and diagnostic algorithms have been developed and periodically updated through international collaboration. Most importantly, numerous pulmonary vasomodulating drugs have been developed, and their widespread use has been associated with longer survival and improved quality of life. Nevertheless, a cure remains elusive.
  • Pulmonary Hypertension Roundtable Recapping Highlights from Pulmonary Hypertension Association Scientific Sessions and Identifying Key Issues Driving Translational Research
  • Pulmonary Hypertension Roundtable: Ethical Considerations for RCTs in PAH A roundtable discussion on ethical issues relating to the conduct of randomized clinical trials (RCTs) with pulmonary arterial hypertension (PAH) patients was held during the May 2009 American Thoracic Society meeting in San Diego
  • The Structure of Pulmonary Hypertension Health Care Delivery: Translating Ethical Considerations into Practice The ethical imperative to provide optimal care to patients applies not only to individual caregivers, but also to the medical community as a whole. Best care frequently requires a team approach.

Presentations